[ad_1]
Johnson & Johnson received approval from Swissmedic, but no doses were ordered. The new positive data from the AstraZeneca study still give hope that vaccines will go faster.
US Study Shows: AstraZeneca vaccine protects 79 percent against corona infection with mild symptoms.
Photo: Piroschka van de Wouw (Keystone)
Pharmaceutical authority Swissmedic has approved a third Covid vaccine: Johnson & Johnson can now inject, aIt has Swiss cans were not ordered from the US group. On the other hand, it could The AstraZeneca vaccine will bring a vaccination boost soon: Dhe has a pact Ihn ordered, and The positive data from the clinical study now makes it clear that it will be approved by Swissmedic.
The federal government has ordered 5.3 million cans from AstraZeneca, which will be the first «very shortly after approval» get here like the speakersin from AstraZeneca Switzerland, he says. The question remains unanswered: has confidence returned?, And do people want to get vaccinated with it? The Federal Office of Public Health hatte in the AstraZeneca vaccination campaign planning already fell and trusted other manufacturers.
100 percent protection against the severe course of Covid
An AstraZeneca clinical study in North and South America now shows that the corona vaccine is safe and also works in older people. Protects 100 percent from a severe course mit Spitalaufenthaltannounced the British-Swedish pharmaceutical company. The vaccine protects 79 percent against a corona infection with mild symptoms. An increased risk of thrombosis was found in the 21‘No 583 subjects were identified who received at least one dose of vaccine.
In Germany and other EU countries The Covid vaccine with AstraZeneca was initially recommended only for younger people due to a lack of data from studies on its effect in older people.. LLast week came due to reports from Thrombosis cases after vaccination. in many EU countries to the vaccination stopP. The European approval authority investigated the cases and then gave the go-ahead. After the turmoil, trust is in AstraWITHeneca was significantly reduced in several European countries.
Not without a special one There are also disputes with the deliveries of the first cans: Switzerland is connected to the EU when it comes to ordering AstraZeneca and is at war with the United States and Great Britain. The EU accusation: Anglo-Saxons have imposed a de facto export ban on the cans they produce. D.that is to say Therefore, the EU and the rest of the world only depend on cans produced in Europe. (Read about this: EU threatens UK with vaccination war)
Switzerland acquires AstraZeneca through the EU via Sweden. This has ordered 300 million cans, including the Swiss order. There has not yet been a deluge of deliveries in the EU gramcome. Due to production problems in Europe, AstraZeneca has currently promised the EU 100 million cans in the first half of the year.
Test series with a good 32,000 volunteers
According to the information, 32,449 test subjects participated in the AstraZeneca phase III clinical study, two-thirds of whom were vaccinated. The others received a placebo. About 20 percent of the participants were 65 years of age or older, and about 60 percent had previous illnesses such as diabetes, which increased the risk of a severe course of Covid 19 disease. In previous studies, almost no evaluated older people or people with previous illnesses. Swissmedic waited therefore, still rely on reliable data from the new study.
